GlassScriptPhysician profile
Yolanda R Cockerham
NPI 1003066606
$10,902.62
in general payments reported to CMS, 2019-2025
21 companies · $3,442 in 2025
The $3,442 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $997 · 2022: $1,263 · 2023: $1,984 · 2024: $3,217 · 2025: $3,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,415 · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,415.28 |
| Education | $227.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,938.18 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,937.10 | 2021-2025 | Ingrezza |
| Abbvie INC. | $1,611.12 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,386.92 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $620.18 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $605.48 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Alkermes, INC. | $515.28 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Lundbeck LLC | $417.70 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $362.71 | 2024-2025 | Uzedy, Austedo Xr |
| Corium, LLC | $286.58 | 2022-2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $245.36 | 2021-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $242.28 | 2024-2025 | Cobenfy |
| Indivior INC. | $146.36 | 2023-2024 | Perseris |
| Collegium Pharmaceutical, INC. | $138.22 | 2025 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $135.64 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $117.55 | 2021-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $79.74 | 2022-2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $45.37 | 2021-2025 | Trintellix |
| Adlon Therapeutics L.P. | $43.45 | 2021 | |
| Tris Pharma INC | $16.24 | 2025 | Dyanavel Xr |
| Lilly USA, LLC | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yolanda Cockerham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.